2011, Provider and Specialization

Diabetes related complications among Ethiopian Jews-Outcomes of a 10 years cohort study in Israel [Population health and epidemiology]

Annals of Family Medicine

NOVEMBER 20, 2024

Population: Jewish CHS members, aged 18+, diagnosed with T2D between 2000-2011, born in Israel or Ethiopia. Conclusions: It is imperative to provide specialized care for immigrant populations to enhance the management of chronic diseases and mitigate further morbidity risks. Intervention: 10-year follow-up to track T2D outcomes.

Complication

Complication Diabetes Individual Chronic Disease

Jennifer Newberger Returns to HPM as a Director After Stints with Apple, Abbott Laboratories, and Cognito Therapeutics

FDA Law Blog

MAY 27, 2024

Jennifer’s combination of experiences as in-house counsel for both large and start-up companies as well as outside counsel provides clients invaluable expertise and problem-solving skills. She also specializes in medical device software and digital health. Ellison, Managing Director at HPM.

Management

Management Manufacturing Utilities Relationship

I Hear You Knockin’… Preparing for and Managing DEA Inspections (Part 1)

FDA Law Blog

MAY 3, 2021

Part 1 provides background and explains the scope of DEA cyclic and on-site inspections. However, more recently, we have observed that DEA special agents are also becoming more involved in investigations of registrants, thus, raising the stakes for compliance. 39,318 , 39,324 (July 6, 2011). 6 (2011) (statement of Michele M.

Management

Management Manufacturing Specialization IT

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

DECEMBER 16, 2020

2011 Sep 20;155(6):408]. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology [published correction appears in J Am Coll Cardiol. Ann Intern Med. 2009;150(9):604-612.

Clinic

Clinic Education Clinical Practice Patient-Centered

I Hear You Knockin’… Preparing for and Managing DEA Inspections (Part 1)

FDA Law Blog

MAY 3, 2021

Part 1 provides background and explains the scope of DEA cyclic and on-site inspections. However, more recently, we have observed that DEA special agents are also becoming more involved in investigations of registrants, thus, raising the stakes for compliance. 39,318 , 39,324 (July 6, 2011). 6 (2011) (statement of Michele M.

Management

Management Manufacturing Specialization IT

Texas invests $50M in psychedelic drug research to treat addiction

Medical Xpress

JUNE 16, 2025

The content is provided for information purposes only. Citation : Texas invests $50M in psychedelic drug research to treat addiction (2025, June 16) retrieved 16 June 2025 from [link] This document is subject to copyright. Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

Mental Health

Mental Health IT Medical Specialization

Rewiring the body clock: Deep brain imaging reveals unexpected complexity in jet lag adjustment

Medical Xpress

JUNE 16, 2025

What is known is that special cells in the eye called intrinsically photosensitive retinal ganglion cells (ipRGCs) detect blue light and send signals to the SCN to reset the clock. The content is provided for information purposes only. Your feedback is important to us.

Provider

Provider Medical Complication Diabetes

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog

DECEMBER 3, 2023

As part of this change, the Coverage Gap Discount Program (CGDP), a program that has existed since 2011, will sunset on December 31, 2024, and be replaced by the Medicare Part D Manufacturer Discount Program (the “Discount Program”). We do not address the technical and administrative details of the Discount Program here.

Manufacturing

Manufacturing Provider IT Electronics

Skinny Label and Induced Infringement: The Saga Continues

FDA Law Blog

MAY 11, 2023

No reasonable jury could have concluded that the carved-out labeling for petitioner’s generic carvedilol from 2007-2011 was itself evidence of intent to induce infringement.” But even if it were that significant, GSK points out that “Congress is the proper forum for the government’s policy-driven argument.” Whether the Court takes up Teva v.

Government

Government Manufacturing IT Utilities

Buprenorphine Use in Serious Illness: A Podcast with Katie Fitzgerald Jones, Zachary Sager and Janet Ho

GeriPal

APRIL 14, 2022

Adapting Palliative Care Skills to Provide Substance Use Disorder Treatment to Patients With Serious Illness . We got some really special guests with us. And that’s a lot easier if all providers were X waivered too. Learn about using the low dose buprenorphine patch: . Transcript. Eric: Welcome to the GeriPal Podcast.

Illness

Illness Patient-Centered IT Patients

Writing for the Lay Public: Rosanne Leipzig and Louise Aronson

GeriPal

MARCH 16, 2023

We have two authors, books, op-eds, prolific authors, and today’s podcast is a two-part special. So this week we’re going to be talking about writing for the lay public, and next week we’ll be publishing a podcast on writing for healthcare providers. Louise: I think that’s his MO. ” Or something.

IT

IT Healthcare Professional Healthcare Transportation

Exploring the Nature of Chronic Pain with Haider Warraich

GeriPal

JULY 7, 2022

Haider: Yeah, this is a special song. And then once I came to the United States, I saw this whole different dimension of pain, because I started residency in 2011, this was really at the peak of the opioid prescription epidemic, if you may. Very, very few centers are providing those services. But my editor cut it, to my dismay.

Patient-Centered

Patient-Centered Physicals IT Patients

Primary Care Digest

Diabetes related complications among Ethiopian Jews-Outcomes of a 10 years cohort study in Israel [Population health and epidemiology]

Jennifer Newberger Returns to HPM as a Director After Stints with Apple, Abbott Laboratories, and Cognito Therapeutics

Trending Sources

I Hear You Knockin’… Preparing for and Managing DEA Inspections (Part 1)

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

I Hear You Knockin’… Preparing for and Managing DEA Inspections (Part 1)

Texas invests $50M in psychedelic drug research to treat addiction

Rewiring the body clock: Deep brain imaging reveals unexpected complexity in jet lag adjustment

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

Skinny Label and Induced Infringement: The Saga Continues

Buprenorphine Use in Serious Illness: A Podcast with Katie Fitzgerald Jones, Zachary Sager and Janet Ho

Writing for the Lay Public: Rosanne Leipzig and Louise Aronson

Exploring the Nature of Chronic Pain with Haider Warraich

Stay Connected